TrianglePUBLICATIONS · 34898239
Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- J Clin Oncol
- Publication date
- 2022 Sep 1
- First author
- Costa LJ
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
Authors and identifiers
- name
- Costa LJ
- type
- Author
- name
- Chhabra S
- type
- Author
- name
- Medvedova E
- type
- Author
- name
- Dholaria BR
- type
- Author
- name
- Schmidt TM
- type
- Author
- name
- Godby KN
- type
- Author
- name
- Silbermann R
- type
- Author
- name
- Dhakal B
- type
- Author
- name
- Bal S
- type
- Author
- name
- Giri S
- type
- Author
- name
- D'Souza A
- type
- Author
- name
- Hall A
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Costa LJ
- type
- Author
- name
- Chhabra S
- type
- Author
- name
- Medvedova E
- type
- Author
- name
- Dholaria BR
- type
- Author
- name
- Schmidt TM
- type
- Author
- name
- Godby KN
- type
- Author
- name
- Silbermann R
- type
- Author
- name
- Dhakal B
- type
- Author
- name
- Bal S
- type
- Author
- name
- Giri S
- type
- Author
- name
- D'Souza A
- type
- Author
- name
- Hall A
- type
- Author
- bibliography ids
- nci-bib-b5935576f04c75255e227412
- book metadata
- content sha256
- 781b0299337c564cf5e8f3f14d6b8a4fd7d95fb08e0d545490e6d90376284328
- document type
- citation
- dois
- 10.1200/JCO.21.01935
- electronic publication date
- display
- 2021 Dec 13
- precision
- day
- year
- 2021
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:34898239
- immutable id
- pubmed:34898239@781b0299337c564cf5e8f3f14d6b8a4fd7d95fb08e0d545490e6d90376284328
- journal
- abbreviation
- J Clin Oncol
- issn electronic
- 1527-7755
- issn print
- 0732-183X
- issue
- 25
- name
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- nlm unique id
- 8309333
- pages
- 2901-2912
- volume
- 40
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- outcomes validated
- false
- pmid
- 34898239
- provenance
- batch id
- 3f4d1914d2afe41e9e70
- provider
- NCBI PubMed ESummary
- record sha256
- 9b29ff4199add53d3ef8b536aefb8d112bb75cf149650bc5d1086b20f01b6a2e
- response sha256
- 0ceeb248a527e54c6f72dd28d20f7abec08a973fe2e10de00bede4895add09e7
- retrieved at
- 2026-09-09T23:48:06.522634+00:00
- publication date
- display
- 2022 Sep 1
- precision
- day
- year
- 2022
- publication types
- Clinical Trial, Phase II
- Journal Article
- Multicenter Study
- Research Support, Non-U.S. Gov't
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma.
Preserved source evidence · Not medical advice